biostudies-literatureUnknown74Huang JF<h4>Background</h4>Masked hypertension is associated with target organ damage (TOD) and adverse health outcomes, but whether antihypertensive treatment improves TOD in patients with masked hypertension is unproven.<h4>Methods</h4>In this multicentre, randomised, double-blind, placebo-controlled trial at 15 Chinese hospitals, untreated outpatients aged 30-70 years with an office blood pressure (BP) of <140/<90 mm Hg and 24-h, daytime or nighttime ambulatory BP of ≥130/≥80, ≥135/≥85, or ≥120/≥70 mm Hg were enrolled. Patients had ≥1 sign of TOD: electrocardiographic left ventricular hypertrophy (LVH), brachial-ankle pulse wave velocity (baPWV) ≥1400 cm/s, or urinary albumin-to-creatinine ratio (ACR) ≥3.5 mg/mmol in women and ≥2.5 mg/mmol in men. Exclusion criteria included secondary hypertensEClinicalMedicine102736https://www.ebi.ac.uk/biostudies/studies/S-EPMC11293515biostudies-literatureEfficacy of antihypertensive treatment for target organ protection in patients with masked hypertension (ANTI-MASK): a multicentre, double-blind, placebo-controlled trial.PMC11293515An DWHu ZLiao YYZhu MYLu YChang GLZhang MYu JDai QYLi XDLi MXChen XPDou YHuang JYLiu HXGuo HZhang YQYu WLiu LXZhu LLXu XLChen XWang JGMa RXZhang DYBu PLXu JTZhang HJMeng QTZhu YFZhang JSMu JJFeng YQZheng QDANTI-MASK InvestigatorsYu YLLiang XYWang WJLi YJiang YNLiu CYStaessen JAZhang YLiu CWang YYHuang JFZhang XNZhang ZPfalseEfficacy of antihypertensive treatment for target organ protection in patients with masked hypertension (ANTI-MASK): a multicentre, double-blind, placebo-controlled trial.<h4>Background</h4>Masked hypertension is associated with target organ damage (TOD) and adverse health outcomes, but whether antihypertensive treatment improves TOD in patients with masked hypertension is unproven.<h4>Methods</h4>In this multicentre, randomised, double-blind, placebo-controlled trial at 15 Chinese hospitals, untreated outpatients aged 30-70 years with an office blood pressure (BP) of <140/<90 mm Hg and 24-h, daytime or nighttime ambulatory BP of ≥130/≥80, ≥135/≥85, or ≥120/≥70 mm Hg were enrolled. Patients had ≥1 sign of TOD: electrocardiographic left ventricular hypertrophy (LVH), brachial-ankle pulse wave velocity (baPWV) ≥1400 cm/s, or urinary albumin-to-creatinine ratio (ACR) ≥3.5 mg/mmol in women and ≥2.5 mg/mmol in men. Exclusion criteria included secondary hypertens2024-01-01T00:00:00Z2024 Aug2026-04-17T13:05:27.142Z2025-04-19T20:48:24.204ZS-EPMC112935153909166910.1016/j.eclinm.2024.102736